Plasminogen activator inhibitor-1 (PAI-1) can occur in three different interconvertible conformations: an active, a latent and a substrate form. We have previously characterized monoclonal antibodies (MAs) with neutralizing properties towards PAI-1. However, these antibodies (Mr=150 kDa) are unlikely to be succcsful for use as therapeutic agents with PAI-1 modulating properties. In this study we report the cloning of the variable domains of the heavy and light chain of one of these antibodies (MA-8H9D4), the expression (in E.coli) as a single-chain variable fragment (scFv) and the characterization of its functional properties. The percentage inhibition of the PAI-1 activity by scFv-8H9D4 (5-fold molar excess) was similar to that observed with the intact antibody (16-fold molar excess) (97 ±16 % and 88 ±10 %, respectively, mean SD, n=3). Furthermore, their influence on the reaction products formed during interaction of PAI-1 with tissue-type plasminogen activator (t-PA), as evaluated by SDS-PAGE followed by densitometric scanning, was also comparable. control MA-8H9D4 scFv-8H9D4 active PAI-1 51±11* 14±5 15±5 latent PAI-1 40±10 45±3 37±12 substrate PAI-1 9±2 42±3 45±4 * expressed as % of total PAI-1 antigen; mean ± SD (n=3); MA-8H9D4 and scFv8H9D4 in 3-fold molar and equimolar excess respectively. In conclusion, we have demonstrated that scFv-8H9D4 fully retains the functional properties of the original MA-8H9D4. This smaller antibody fragment (Mr - 24 kDa) may serve as a starting point for the design of pharmacological compounds for the treatment of patients with increased PAI-1 levels.

Molecular cloning and characterization of an antibody fragment (SCFV) that converts plasminogen activator inhibitor-1 from inhibitor to substrate / S. Debrock, L. Sironi, P.J. Declerck. - In: FIBRINOLYSIS. - ISSN 0268-9499. - 10:suppl. 3(1996), pp. 36-36. [10.1016/s0268-9499(96)80201-3]

Molecular cloning and characterization of an antibody fragment (SCFV) that converts plasminogen activator inhibitor-1 from inhibitor to substrate

L. Sironi;
1996

Abstract

Plasminogen activator inhibitor-1 (PAI-1) can occur in three different interconvertible conformations: an active, a latent and a substrate form. We have previously characterized monoclonal antibodies (MAs) with neutralizing properties towards PAI-1. However, these antibodies (Mr=150 kDa) are unlikely to be succcsful for use as therapeutic agents with PAI-1 modulating properties. In this study we report the cloning of the variable domains of the heavy and light chain of one of these antibodies (MA-8H9D4), the expression (in E.coli) as a single-chain variable fragment (scFv) and the characterization of its functional properties. The percentage inhibition of the PAI-1 activity by scFv-8H9D4 (5-fold molar excess) was similar to that observed with the intact antibody (16-fold molar excess) (97 ±16 % and 88 ±10 %, respectively, mean SD, n=3). Furthermore, their influence on the reaction products formed during interaction of PAI-1 with tissue-type plasminogen activator (t-PA), as evaluated by SDS-PAGE followed by densitometric scanning, was also comparable. control MA-8H9D4 scFv-8H9D4 active PAI-1 51±11* 14±5 15±5 latent PAI-1 40±10 45±3 37±12 substrate PAI-1 9±2 42±3 45±4 * expressed as % of total PAI-1 antigen; mean ± SD (n=3); MA-8H9D4 and scFv8H9D4 in 3-fold molar and equimolar excess respectively. In conclusion, we have demonstrated that scFv-8H9D4 fully retains the functional properties of the original MA-8H9D4. This smaller antibody fragment (Mr - 24 kDa) may serve as a starting point for the design of pharmacological compounds for the treatment of patients with increased PAI-1 levels.
Settore BIO/14 - Farmacologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0268949996802013-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 138.28 kB
Formato Adobe PDF
138.28 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/722904
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact